Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100188Source: DataRank Database

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma is a research paper published in JTO Clinical and Research Reports (2021). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (11 grants)Impact (FWCI 0.26)OA: goldTopics (21)IDs (PubMed, PMC, OpenAlex)Annotations (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Nandita Mitra ORCID,Stephen Bagley ORCID,Melina E. Marmarelis ORCID,Andrew R. Haas,Katharine A. Rendle ORCID

Live enrichment

PubMed:34590032 PMC:PMC8474474 OpenAlex:https://openalex.org/W3161847425

National Institutes of Health

Grant: T32 HL-007891

National Institute of Environmental Health Sciences

Grant: P30-ES013508

NHLBI NIH HHS

Grant: T32 HL007891

NIEHS NIH HHS

Grant: P30 ES013508

AbbVie

Pfizer

Gilead Sciences

Portola Pharmaceuticals

AstraZeneca

GlaxoSmithKline

Merck

FWCI

0.26

Citation Percentile

0.5%

Citation Trend

2023

2025

2026

goldLicense: cc-by-nc-nd

journalhttp://www.jtocrr.org/article/S2666364321000473/pdf

publisherhttp://www.jtocrr.org/article/S2666364321000473/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2666364321000473?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2666364321000473?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jtocrr.2021.100188

Fields of Study

Occupational and environmental lung diseasesCancer Immunotherapy and BiomarkersLung Cancer Research Studies

Keywords

MedicineInterquartile rangeGuidelineMesotheliomaInternal medicineOdds ratioCohortRetrospective cohort studyCancerResponse Evaluation Criteria in Solid TumorsOncologyChemotherapyPathologyProgressive diseaseHistologyUptakeImmunotherapyReal-world Evidence

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma

FAIR Checklist

Authors (7)

Funding (11 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)